Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLC

Name: Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLC
Uploaded: 2018-09-28T06:10:00.000Z
Description: Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

September 28, 2018

Mark G. Kris, MD, FASCO

Video

In Partnership With:

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.